Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BILB 1941 ZW in Healthy Males
NCT02256787Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2004
- Primary completion
- Sep 2004
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of BILB 1941 ZW in hepatitis C (HCV) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of subjects with abnormal findings in physical examination up to 48 hours, Number of subjects with abnormal changes in laboratory parameters up to 48 hours and 4 more. Started Jan 2004; status: completed.
02
Drugs
BILB 1941 ZW
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02256787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02256787.